Navigation Links
SuperGen Reports 2008 First Quarter Financial Results
Date:4/28/2008

I-1776, our lead PIM kinase inhibitor, was found to cause tumor

regression in acute myologenous leukemia (AML) xenograft models

(Abstract No. 4974). In an oral presentation entitled, "A potent

small molecule PIM kinase inhibitor with activity in cell lines from

hematological and solid malignancies," Dr. Steven Warner, SuperGen's

Manager, Discovery Biology, detailed how scientists used the

Company's CLIMB(TM) technology to build a model that allowed for the

creation of small molecule PIM kinase inhibitors. SGI-1776 was

identified as a potent and selective inhibitor of the PIM kinases,

inducing apoptosis and cell cycle arrest, thereby causing a

reduction in phospho-BAD levels and enhancement of mTOR inhibition

in vitro. SGI-1776 induced significant tumor regression in MV-4-11

(AML) and MOLM-13 (AML) xenograft models.

-- MP-470, a clinical-stage multi-targeted tyrosine kinase inhibitor

and Rad51 suppressor, was shown to be bioavailable and safe in

humans (Abstract No. 4083). The presentation entitled, "MP-470, a

potent oral Rad51 suppressor is safe and tolerable in first-in-human

study," summarized the data indicating that MP-470 can be safely

administered in doses of up to 900 mg per day. Additionally, it was

found that Rad51 expression is modulated in a dose-dependent manner.

This is consistent with pre-clinical studies where MP-470 was shown

to sensitize cancer cells to DNA damaging agents and radiation

therapy by suppressing Rad51, a protein responsible for repair of

double strand DNA breaks in cancer cells.

-- MP-470 was shown to effectively sensitize prostate and breast cancer

cells to erlotinib (Abstract No. 671). The presentation entitled,

"Inhibition of
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... days of demostrating Wisconsin's breakthroughs in biotechnology, the Wisconsin ... a discussion of what the state must do to attract ... Wisconsin has made in research, but explained without capital they ... moderator of the panel and president of the Wisconsin ...
... acquire AccuImage Diagnostic Corp. to expand its ... announced on Wednesday. , ,Merge eFilm, the business name ... with the San Francisco-based company in first-quarter 2005. , ... includes three-dimensional visualization tools that can be used for ...
... Milwaukee Metavante Corp. said it ... , which makes software that handles bank transactions and ... Marshall & Isley Corp, said in October that ... the software company into a wholly owned subsidiary. The ...
Cached Biology Technology:Out-of-state VCs offer advice on biotech investments 2Out-of-state VCs offer advice on biotech investments 3
(Date:11/18/2014)... Nov. 18, 2014  The Secure Identity & ... today jointly announce the formation of The Airport ... its Identity and Biometric Entry and Exit ... received official support from BORDERPOL, the international non-profit ... and provide expertise regarding border security, traveler and ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... to put a price tag on the natural world? A ... rise of a new concept ecosystem services to ... Nature. Academic Dr Marion Potschin, of the University,s Centre ... who have been investigating the ethical considerations of this new ...
... . , Biopesticides containing beneficial fungi are ... Department of Agriculture (USDA) scientists have shown a liquid ... "liquid culture fermentation," offers several benefits, including lower material ... fungi, including Isaria or Metarhizium , ...
... CALGARY Researchers in Calgary have launched the first gene therapy ... enzyme deficiency that can shorten the lifespan of people who have ... first remove a quantity of stem cells from a Fabry patient,s ... inserted into the stem cells using a specially engineered virus. During ...
Cached Biology News:Valuing nature is not enough 2New, cost-cutting approach to formulating pest-killing fungi 2Canada launches first gene therapy trial for Fabry disease 2Canada launches first gene therapy trial for Fabry disease 3
...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... l-[35S]in vitro cell labeling mix, ... *Aqueous solution stabilized with 0.1% ... pyridine 3,4-dicarboxylic acid. *Amino acid ... labeling containing l-[35S]Methionine and l-[35S]Cysteine. ...
...
Biology Products: